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EXECUTIVE SUMMARY 
 
The Northeast Regional Cancer Institute has conducted a program of epidemiologic 
research to address cancer disparities in northeast Pennsylvania.  This program 
includes surveillance of common cancers, investigations of cancer risk factors and 
screening behaviors, and the development of resources to further cancer research in 
this community. 
   
Cancer surveillance was conducted using data from the Northeast Regional Cancer 
Institute’s population-based Regional Cancer Registry, the Pennsylvania Cancer 
Registry, and NCI’s SEER program.  For common cancers, incidence and mortality 
were examined by county within the region and compared to data for similar populations 
in the US.  In addition, a population-based interview study of healthy adults was 
conducted to document the status of cancer screening and to estimate the prevalence 
of established cancer risk factors in this community. 
 
Both incidence of and mortality from cancer at all sites combined were slightly (3 to 5 
percent) but significantly elevated in northeast Pennsylvania.  For cancers of the colon 
and rectum, urinary bladder and esophagus, both incidence and mortality were 
substantially elevated.  For eight primary sites, incidence was elevated but mortality was 
not significantly different from US figures.  For several cancers (breast, prostate, 
malignant melanoma, multiple myeloma, and liver), incidence rates were significantly 
lower than US figures.  Over time, the incidence of colorectal cancer has decreased and 
the proportion of new cases diagnosed at local stage increased, but in 1999-2003, 
incidence and mortality rates for this cancer remained 26% and 25% higher, 
respectively, than the corresponding US figures.  
 
The proportions of adults 50 years and older who were adequately screened for cancers 
of the colon and rectum, female breast, cervix, and prostate were 41.5%, 55.6%, 74.9%, 
and 47%, respectively.  Colorectal cancer screening increased over time and reached 
48.3% in 2006.  However, mammography use decreased over time and was only 50% 
by 2006. 
 
An analysis of cancer risk factors documented that cigarette smoking was significantly 
more common in this population (26.7% of adults were current smokers) than in 
Pennsylvania or the US.  Further, lack of regular exercise, a high prevalence of obesity, 
and diets low in fiber and high in fat were also observed. 
 
In summary, this project documents the patterns of cancer incidence and mortality in a 
six-county region of northeast Pennsylvania.  Several cancers with unusually high 
incidence and mortality rates were identified.  The prevalence of cancer screening 
practices and selected risk factors were also documented. 
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SUMMARY OF PROJECT ACTIVITIES 
 
Background 
Cancer is the second leading cause of death in US.1  It is second only to heart disease 
overall, and is the leading cause of death among Americans younger than 80 years of 
age.1  Among cancers, colorectal cancer is second only to lung cancer as a cause of 
death.1  It has been estimated that in 2005, colorectal cancer was diagnosed in 145,000 
Americans and approximately 56,000 died from this disease.2 Both incidence and 
mortality rates are greater in men than women and in blacks compared to whites.3 
 
Except for a brief increase between 1995 and 1998, the incidence of colorectal cancer 
in the United States has been decreasing since 1985.3 Effective screening tests for 
colorectal cancer such as colonoscopy are available and recommended for populations 
at risk. The increase in incidence between 1995 and 1998 may have been due to 
increased case detection by screening, but this has not been documented. 
 
If diagnosed early (as a pre-cancerous polyp or local stage disease), colorectal cancer 
is readily treated and the prognosis is very good. Regardless of the underlying etiology, 
most colorectal cancers develop from polyps.  These abnormalities of the mucosal 
surface may begin as entirely benign lesions that over time develop carcinoma in situ 
and then progress to invasive carcinoma.  The prevalence of adenomatous polyps in 
the U.S. is about 25% by age 50 and may increase to as high as 50% by age 70.4 It has 
been estimated that approximately 15% of adenomas larger than 1cm will progress to 
cancer over 10 years.5 Longitudinal studies have documented an increased risk of 
colorectal cancer in individuals with adenomatous polyps who do not have them 
removed and a lower risk among those who have had polypectomies.6, 7   
 
Despite evidence that screening for colorectal cancer can reduce mortality from (and 
incidence of-) this cancer, the actual use of these screening tools remains low.8-12  In 
2002, 50% of American men and women aged 50 years and older reported that they 
had not been appropriately screened for colorectal cancer (having had a fecal occult 
blood test [FOBT] in the previous year or sigmoidoscopic or colonoscopic screening in 
the previous five years).13  It has been estimated that 90% of colorectal cancer deaths 
could be prevented with early detection and aggressive treatment. 
 
Colorectal cancer in northeast Pennsylvania:  In the six-county area of northeast 
Pennsylvania (Lackawanna, Luzerne, Pike, Susquehanna, Wayne, and Wyoming 
counties), the incidence of cancer overall (all sites combined) is only slightly higher than 
the US average.  For the years 1996-2000, the standardized incidence ratio (SIR), 
defined as the ratio of cases observed: to cases expected, was 102 (95% confidence 
interval [CI], 100.1-103.7).  However during this same period, the SIR for colorectal 
cancer overall was 125 (95% CI, 120.8-129.4).  Among men, the SIR was 134 (95% CI, 
127.1-140.0), and among women, it was 117 (95% CI, 111.7-123.2).  Historically, 
colorectal cancer mortality has also been higher in several northeast Pennsylvania 
counties than the U.S. as a whole.  A 24-year review of age-adjusted colorectal cancer 
mortality rates was recently published by the National Cancer Institute.14 This Atlas of 
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Cancer Mortality in the United States 1950-94, includes county-specific colorectal 
cancer mortality rates for each county in the US.  Colorectal cancer mortality among 
white men living in Lackawanna, Luzerne, and Wayne counties between 1970 and 1994 
were among the highest 10% of counties in the U.S.  Pike and Wyoming counties had 
the lowest mortality rates in the area, which were near the US median.  The distribution 
of county-specific colon cancer mortality rates for white women was similar.  Mortality 
rates for women in Lackawanna and Luzerne counties were among the highest 10% of 
counties in the US, while Wayne County ranked in the 2nd highest decile.  Mortality in 
the remaining counties is lower, but none was below the 60th percentile for US counties.   
 
The higher mortality rates are likely influenced by a higher incidence of regional stage 
disease in this community.  In Lackawanna County between 1994 and 1998, 53% of 
patients with colorectal cancer were diagnosed with regional stage disease, compared 
to 38% in the National Cancer Institute’s Surveillance Epidemiology and End Results 
(SEER) program registries (Figure 1.).  Compared to patients in the SEER registries, a 
significantly smaller proportion of patients in Lackawanna County were diagnosed at the 
local stage.  The proportions of patients with distant stage colorectal cancer were similar 
in these two populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The reasons for the higher incidence of more advanced stage disease in northeast 
Pennsylvania are not yet clear, but screening practices most likely contribute to this 
disparity.  Diminished access to early detection services or delayed diagnostic 
evaluation after an abnormal screening test might be the pathway to diagnosis of cancer 
at a late stage 15 Socioeconomic disadvantage may result in diminished access to early 
detection services or in delayed diagnostic evaluation after an abnormal screening test. 
Figure 1.  Colorectal cancer stage at diagnosis among whites of both sexes in 
Lackawanna County 1994-98 and NCI’s SEER Registries 1992-97.  
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Among those who are socio-economically disadvantaged, cultural views and practices 
may inhibit health care seeking behavior in general and cancer screening in particular.15 
It is likely that attitudes toward screening, actual screening practices, and perceived 
barriers to screening contribute to stage at diagnosis of colorectal cancer.   
 
An understanding of the factors that influence screening in an at-risk, underserved 
population as well as a more thorough understanding of risk factors for this common 
cancer could potentially illuminate those factors that contribute to colorectal mortality 
nationally. 
 
Cancer Institute Objectives:  The long-term goals of The Northeast Regional Cancer 
Institute are to reduce the burden of cancer (morbidity and mortality) among the 
residents of northeast Pennsylvania.  In particular, we wish to address the disparities in 
incidence of- and mortality from colorectal cancer in this population.  To this end, we 
have developed a two-pronged approach.  We have established a program to increase 
awareness of colorectal cancer and the benefits of screening for this disease in both the 
professional and lay communities in northeast Pennsylvania.  This Targeted Colorectal 
Cancer Awareness Program (TCCAP) was begun in 2004 and is supported by other 
funds.  In addition, we wish to study risk factors for and the etiology of colorectal cancer 
in this high-risk community. 
 
It is well established that currently available screening procedures can not only reduce 
colorectal cancer mortality, but can reduce incidence as well.8-11  The Northeast 
Regional Cancer Institute’s TCCAP program was designed to educate physicians (and 
other health care providers) about the unusually high incidence of colorectal cancer in 
northeast Pennsylvania, the low proportion of cases detected at an early stage, and the 
clear benefits of screening.  In addition, a parallel effort is being conducted to directly 
educate the lay public about the need for and benefits of colorectal cancer screening.  
This program was begun in early 2004 and continued into early 2007.   
 
A review of cancer surveillance data from the Cancer Institute’s Regional Cancer 
Registry indicates that, over time, the proportion of colorectal cancer patients diagnosed 
at local stage is improving.  During the years 1993-1997, 22% of new cases were 
diagnosed at the local stage, between 1998 and 2002, this proportion increased to 31%, 
and by 2004, it was 41%.  The distribution of stage at diagnosis of colorectal cancer 
cases between 1998 and 2004 is shown in Figure 2.  In addition, an analysis of cancer 
screening data has demonstrated a material improvement in colorectal cancer 
screening rates in the community.  Between 2001 and 2002, the proportion of adults 50 
years and older in northeast Pennsylvania who had had a screening colonoscopy or 
sigmoidoscopy in the previous five years was 33%; by 2003, this figure had increased to 
42%, and in 2004, it was 39%.  This increase in the prevalence of colorectal screening 
was statistically significant (p <0.05).  Both of these observations suggest that Cancer  
Institute’s educational efforts are having the desired effect (increasing screening rates 
and the proportion of colorectal cancer patients diagnosed with early stage disease).   
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Objectives of the current project:  Under the current funding, we have continued our 
population-based surveillance of cancer in northeast Pennsylvania, have investigated 
cancer screening practices and examined the prevalence of cancer risk factors in this 
population.   
 
This project had the following specific aims: 
 
I. To conduct cancer surveillance in northeast Pennsylvania. 
a. To monitor incidence and mortality for all common cancers, and colorectal 
cancer, in particular, and  
b. To document changes in the stage at diagnosis of colorectal cancer in this 
high-risk, underserved community. 
 
II. To conduct a population-based study of cancer risk factors and screening 
behavior in northeast Pennsylvania. 
a. To monitor and document changes in cancer screening rates, and  
b. To document the prevalence of cancer risk factors (especially factors that 
increase the risk of colorectal cancer) and to identify any risk factors that 
are unusually common in this community. 
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Figure 2.  Stage at diagnosis of colorectal cancer cases diagnosed in Northeast Pennsylvania by year, 1998-2004. 
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This report describes the results of these activities. 
Methods 
We conducted cancer surveillance using data from the Northeast Regional Cancer 
Institute’s population-based regional cancer registry, the Pennsylvania Cancer Registry, 
and SEER program data.  For the 23 most common cancers in northeast Pennsylvania, 
we examined incidence by county within the region and compared these figures to 
similar data for all of Pennsylvania and similar populations in the US.  We used data 
from these same sources to compare mortality rates for the 23 most common cancers in 
northeast Pennsylvania.  We examined cancer mortality by county within the region and 
compared these figures to corresponding figures for Pennsylvania and the US.  These 
analyses of incidence and mortality data were not limited to colorectal cancer but 
included the other common cancers.  For colorectal cancer, we compared the stage at 
diagnosis of recent cases to those diagnosed in prior years. 
 
We also conducted a population-based study of healthy adults living in northeast 
Pennsylvania to document the current status of cancer screening in this community and 
to estimate the prevalence of established risk factors for a variety of cancers, including 
colorectal cancer.  This study is similar in design to that used by the Centers for 
Disease Control and Prevention’s (CDC) Behavioral Risk Factor Surveillance System 
(BRFSS).  However, we gathered data exclusively from a large sample of adult 
residents of northeast Pennsylvania.  We used these data to monitor the prevalence of 
colorectal cancer screening (ie, FOBT, and sigmoidoscopy or colonoscopy) and 
changes in the utilization of these procedures over time. 
 
Experimental methods and procedures:  This program included two distinct but 
related projects.  The first project used existing data to conduct cancer surveillance in 
northeast Pennsylvania, and the second was a population-based study of cancer risk 
factors and cancer screening behaviors in this same population. 
 
Objective I- Cancer Surveillance:  Cancer is a reportable disease in Pennsylvania, 
and all hospitals and clinics must report each case of cancer diagnosed or treated in 
that facility to the Pennsylvania Cancer Registry.  In northeast Pennsylvania, this 
reporting function is performed largely by a population-based regional cancer registry 
operated by The Northeast Regional Cancer Institute. 
 
Started in 1994, The Northeast Regional Cancer Institute’s cancer registry, which 
serves all of Lackawanna County and portions of Luzerne and the other surrounding 
counties, is the first collaborative regional cancer registry in Pennsylvania.  The registry 
provides cancer registry services to 9 hospitals.  Certified cancer registrars employed by 
The Northeast Regional Cancer Institute review records at these clinical sites and 
abstract data on all incident cancer cases and collect follow-up data, including 
treatment, on all prevalent cancer cases.  The registry records patient demographic 
information (age, race, sex), county of residence, and detailed clinical information about 
each incident cancer case, including primary site, histology, stage (both AJCC and 
SEER summary stage are recorded), and all cancer treatments (surgery, radiation, 
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chemotherapy, biologic response modifiers, and other new or novel therapies).  The 
data are reviewed at the regional cancer registry office and cleaned prior to submission 
to the Pennsylvania Cancer Registry.  All cancer data reported to the Pennsylvania 
Cancer Registry from participating hospitals are processed by The Northeast Regional 
Cancer Institute’s registry.  Since its inception, the Regional Cancer Registry has 
collected incidence and follow-up data on more than 73,000 cancer cases, including 
more than 9,870 cases of colorectal cancer.  The Regional Cancer Registry has been 
population-based for Lackawanna County since 1998.  Over the past five years, this 
registry has identified and gathered data on an average of more than 455 incident 
colorectal cancer cases per year.   
 
The Pennsylvania Cancer Registry has been collecting population-based cancer 
incidence data from all counties in Pennsylvania since 1985.  This resource includes all 
of the data on incident cancer cases described above but does not contain follow-up 
data on patients subsequent to diagnosis and initial treatment.  County level (i.e., 
aggregate) data on cancer incidence by anatomic site for the most common cancers are 
made available for research purposes. 
 
Incidence analyses:  Using cancer registry data, we calculated standardized incidence 
ratios (with 95% confidence intervals) for the 23 most commonly diagnosed cancers in 
northeast Pennsylvania.  Separate calculations were performed for men, women, and 
both sexes combined (where appropriate) and for each of the six counties in northeast 
Pennsylvania.  The expected number of cases for these calculations was estimated by 
applying the age-specific cancer incidence rates from NCI’s SEER program to the age 
distribution in each county.  The results were summarized in tabular form and displayed 
on a series of maps showing the distribution of cancer incidence by county in northeast 
Pennsylvania.  Counties for which cancer incidence is significantly different from the 
expected figure were indicated by a special color (dark red for significantly elevated, 
dark blue for significantly lower than expected).  Separate maps were generated for 
each combination of cancer site and sex.  These results were reviewed for evidence of 
higher than expected incidence of these common cancers or evidence of spatial 
patterns in cancer incidence within the region.  In addition, the data were compared to 
previous calculations for evidence of any change in incidence. 
 
Mortality analyses:  Similar to the analysis described above, we also calculated 
standardized mortality ratios (with 95% confidence intervals) for the 23 most common 
cancers in northeast Pennsylvania.  The expected number of deaths was calculated by 
applying age-specific death rates from the SEER program to the age distribution of the 
population in each county.  The results were summarized in tabular form and displayed 
on maps.  Separate maps were generated for each combination of cancer site and sex.  
These results were reviewed for evidence of higher than expected mortality of these 
common cancers or spatial patterns in cancer mortality within the region.  In addition, 
the data were reviewed for evidence of a change in mortality from previous calculations.   
 
Colorectal cancer analyses:  For colorectal cancer, we performed the following 
additional calculations.  We computed age-adjusted incidence rates (overall and by sex) 
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by year.  These latter data were used to assess changes in colorectal cancer incidence 
over time.  We also examined the distribution of stage-at-diagnosis of incident colorectal 
cancer cases by year of diagnosis.  
 
Objective II- Population-based study of cancer risk factors and screening: 
We conducted a study of cancer risk factors and screening behaviors in northeast 
Pennsylvania.  The study uses an anonymous telephone survey using random digit 
dialing to contact a representative sample of adult residents of the area.  Methods are 
similar to those used by the CDC’s BRFSS.  All English-speaking persons, age 18 and 
older, regardless of sex, race, ethnicity or income, have an equal chance of being 
included in the study.  After a household is contacted, the resident whose next birthday 
is nearest the date of contact is selected as the study participant.  When an eligible 
subject is reached, the study is explained, verbal consent is obtained, and a trained 
member of the research staff interviews the subject using a structured interview 
schedule.  (This selection scheme is similar to that used by the BRFSS.)  Data are 
collected by specially-trained interviewers who received extensive training in 
administration of the instrument, medical terminology, and screening practices.  The 
interview is conducted using a computer-assisted interview system, and responses are 
recorded directly into computer files. We have conducted approximately 1,000 surveys 
annually among residents of northeast Pennsylvania. 
 
Interview Data: The following data are collected as part of this study: 
• General data – including age, sex, race, ethnicity, religion, marital status, 
education, employment status, occupation, and date of interview. 
• Place of residence – subjects will be classified as residing in an “urban” 
community if their current place of residence (city, borough, or township) is in a 
community which has a population density greater than 500 people per square 
mile and a total population > 2500.  All other subjects will classified as residing in 
a “rural” community. 
• Source of health care - the subject’s usual source of medical care (private 
physician, nurse practitioner, emergency room/urgent care center, or none) will 
be recorded. 
• Medical history – we will record the subject’s self-reported history of diabetes, 
hypertension, hyperlipidemia, myocardial infarction, intestinal polyps, 
inflammatory bowel disease and familial andeomatous polyposis (including age 
at first diagnosis). 
• Reproductive history (women only) – we will record the subject’s parity and 
menopausal status. 
• Medication use – we will gather data on the subject’s life-time use of a limited 
category of medications (non-steroidal anti-inflammatory drugs [NSAIDs] and 
statins). 
• Diet – we will gather data on usual dietary practices using a brief food frequency 
questionnaire (Block dietary screener).  This tool permits estimation of total 
caloric intake, calories from fat, fiber intake and frequency of consumption of 
approximately 25 specific foods. 
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• Colorectal cancer screening – a history of fecal occult blood testing (FOBT) 
will be recorded as ever/never.  Interval since most recent prior screening is 
available for those who report having ever been screened.  Information on 
history of lower endoscopy (sigmoidoscopy or colonoscopy) is recorded as 
ever/never.  Interval since most recent prior endoscopic screening is available 
for those who report have ever been screened by this method.  Very few 
participants report screening by other methods (barium enema, “virtual 
colonoscopy”, or fecal DNA testing). 
• Other cancer screening - the subject’s prior screening practices, including the 
interval since most recent mammography and PAP testing for women and 
prostate specific antigen (PSA) testing for men. 
• Other health-related screenings – the subject’s prior screening practices, 
including the interval since most recent diabetes and cholesterol screenings. 
• Family history of any cancer – the occurrence of cancer at any site among first 
degree relatives. 
• Family history of colorectal cancer – the occurrence of colorectal cancer in 
first-degree relatives. 
• Tobacco and alcohol use – tobacco and alcohol use including present status 
(current, former, never), duration of use (in years), and amount (cigarettes and 
drinks per day). 
• Physical activity – exercise activity including type, duration, and frequency. 
• Height and Weight – information on current height and weight, which will be 
used to compute Body Mass Index (BMI). 
 
Data Analysis:  The specific aims of this study are largely descriptive, and the analysis 
were straight-forward.  
 
Prior to any analysis, the data were examined for missing items, inconsistent data, and 
outliers.  Individual data records identified during this process were examined, and any 
coding errors documented.  Variables for which the data remain missing were coded as 
“Unknown.”  Descriptive statistics characterizing the subjects interviewed were 
generated.  Descriptive statistics characterizing the population enrolled were generated.  
Continuous variables were summarized by calculating their means (and corresponding 
standard error of the mean); categorical variables were summarized as proportions (and 
their corresponding 95% confidence intervals).  In comparisons between subgroups, 
continuous variables were assessed using Student’s t-test for unpaired data, and 
categorical variables were assessed using the chi square test or Fisher’s exact test, as 
appropriate.    
 
Results 
Cancer Surveillance:  Standardized incidence ratios (SIRs) for 23 cancer sites overall 
and by sex for 1998-2002 and 1999-2003 are shown in tables 1 and 2.  Color coded 
maps displaying the SIRs for each cancer by county in northeast Pennsylvania were 
produced and are shown at the Cancer Institute’s website 
(http://www.cancernepa.org/web/professionals/search/home.asp).  For 1998-2002, incidence for 
all cancer sites combined was slightly higher than predicted based on SEER program 
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rates (SIRall sites = 103 (95% confidence interval [CI], 102-105).  Incidence was 
significantly elevated for eleven cancer sites (colon and rectum, bronchus and lung in 
men, esophagus, larynx, thyroid, urinary bladder, Hodgkin’s Lymphoma, testis, ovary, 
uterine corpus and uterine cervix). Incidence rates were significantly lower than SEER 
rates for five sites (liver and intra-hepatic bile ducts, multiple myeloma, malignant 
melanoma, prostate and female breast), and not significantly different from expected for 
the remaining sites. These relationships were replicated when 1999-2003 data were 
analyzed. 
 
Age-adjusted incidence rates for colorectal cancer have been calculated, and compared 
to rates for previous years.  Incidence for this cancer site has decreased but remains 
significantly higher than the rate in the SEER program registries.  The age-adjusted 
incidence rate for colorectal cancer in 2000 was 69.8 cases per 100,000; in 2005, the 
corresponding rate was 63.0 cases per 100,000.  This decrease parallels the trend in 
U.S. colorectal cancer incidence as reflected in the SEER program registries. 
 
The distribution of invasive colorectal cancers by stage at diagnosis has been 
monitored.  The improvement in stage at diagnosis first seen in cases diagnosed in 
2004 has continued among cases diagnosed in 2005.  The prevalence of local stage 
disease among colorectal cancer cases diagnosed in the periods1998-2003 and 2004-
2005 were 30.9% and 38%, respectively.  This represents a statistically significant 
improvement in stage at the time of diagnosis (p < 0.0001).  Data on stage at diagnosis 
for cases diagnosed during 2006 were not available at the end of the project period. 
 
Standardized mortality ratios (SMRs) for cancers at 23 sites and all sites combined are 
shown in tables 3 and 4. Color coded maps displaying the SMRs for each cancer by 
county in northeast Pennsylvania were produced and are shown at the Cancer 
Institute’s website (http://www.cancernepa.org/web/professionals/search/home.asp).  For the 
period 1998-2002, cancer mortality in northeast Pennsylvania was slightly higher than 
the U.S. cancer mortality rate for all cancer sites combined (SMRall sites = 103; 95% CI, 
101-105).  The excess in mortality was statistically significant only for men (SMR = 105; 
95% CI, 102-108).  Compared to U.S. cancer mortality rates, mortality in northeast 
Pennsylvania was significantly elevated for cancers of four sites (colorectum, urinary 
bladder, esophagus, and ovary) and significantly lower for only cancers of the lung and 
bronchus in women.  Several minor differences are seen when the results of our 
analysis of 1999-2003 data are compared to these results.  For this period, the overall 
SMR was 105 (95% CI 103–106), but was significantly elevated only among men (SMR 
= 108; 95% CI 105-111). The SMR for cancer of the ovary was not significantly 
elevated, but the SMR for cancers of the larynx in men was.  In addition, SMRs for 
cancers of the liver and intra-hepatic bile ducts and multiple myeloma were significantly 
reduced. 
 
When the surveillance data from both time periods and for both incidence and mortality 
are considered, cancers at three sites stand out.  Both incidence and mortality are 
significantly and consistently elevated for cancers of the colon and rectum, urinary 
bladder, and esophagus in men.  These three cancer sites may be considered for 
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further investigation as priority cancers in this community.  The observation that breast 
cancer in women and prostate cancer in men are diagnosed significantly less often than 
expected, suggests that screening for these cancers may be less intense in this 
community than in the general US population.  The change in colorectal cancer stage-
at-diagnosis is compatible with an appropriate community response to the Cancer 
Institute’s TCCAP program. 
 
A manuscript describing the high incidence and mortality for colorectal cancer in 
Lackawanna County, Pennsylvania has been accepted for publication in the Journal of 
Registry Management.  Publication is expected in the Fall of 2007. 
 
Cancer Screening:  The prevalence of colorectal cancer screening was examined for 
the years 2001 to 2006.  During this period, the prevalence of screening endoscopy 
(colonoscopy or flexible sigmoidoscopy) has increased and the prevalence of screening 
using fecal occult blood testing (FOBT) does not appear to have changed significantly.  
In 2001-2002, 33% of the adult population 50 years and older reported having been 
screened by endoscopy in prior five years; for the period 2003-2006, the prevalence of 
use of this screening test had increased to 41.5%.  This represents a statistically 
significant increase in the prevalence of screening endoscopy (p < 0.0001).  In the most 
recent single year period for which data were available, 2006, the prevalence was 
48.3%.  The prevalence of screening by FOBT was also examined by year of interview.  
Because of changes in the methods used, data on FOBT use for the years 2001 and 
2002 cannot be compared to that collected in more recent years.  During 2003-2004, 
28.2% of adults reported having been screened by FOBT in the prior two years.  The 
corresponding figure for 2005-2006 was 26.8%.  
 
Data have been analyzed to identify predictors of or barriers to colorectal cancer 
screening in this population; a manuscript describing the results is in preparation. 
 
Prevalence estimates for breast, prostate, and cervical cancer screening have been 
calculated.  For the period 2001-2006, 57.5% of women age 40 years and older 
reported having had a clinical breast exam in the prior year, and 55.6% reported having 
had a mammogram within the prior year.  During this same period, 63% of men age 50 
years and older reported having ever had a prostate-specific antigen (PSA) test, and 
47% had this test within the prior year.  Among women age 18 years and older, 97% 
reported having ever had a Pap test, and 74.9% reported having this test in the prior 
two years. 
 
A more detailed analysis of breast cancer screening was conducted among women 
living in Luzerne County, the largest county in northeast Pennsylvania.  This analysis, 
which included examination of screening practices in the city of Wilkes-Barre, the 
county seat, is included here.  Data were available for 942 women 40 years and older 
living in Luzerne County.  Of these women, 149 lived in Wilkes-Barre.  BRFSS data 
were available for 11,031 women in Pennsylvania.  The proportions of women who 
reported having a clinical breast exam or mammogram are shown in Table 5.  Among 
Luzerne County women 40 and older, 60% had a clinical breast exam in the prior year.  
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This figure is significantly lower than the corresponding figure for women living in all of 
Pennsylvania (65%).  The figure for women living in Wilkes-Barre was 58%, but this was 
not statistically different from either the figures for Luzerne County or Pennsylvania as a 
whole.  The figures for mammogram use show a similar pattern.  Among women 40 and 
older in Luzerne County, 58% reported having a mammogram in the prior year.  This 
figure is significantly lower than the figure for mammogram use among all Pennsylvania 
women (62%).  Among residents of Wilkes-Barre, 61% reported having a mammogram 
in the prior year.  The proportion of women 50 years and older who had both a clinical 
breast exam and mammogram in the prior two years is also shown in Table 5.  Seventy 
% of women in Luzerne County reported having both screening tests in the prior two 
years; the corresponding figure for Pennsylvania was also 70%, and for Wilkes-Barre it 
was 66%.  Mammography use according to age and education level is shown in Table 
6.  Among Luzerne County women, mammography use was lowest among the 
youngest and oldest women.  Only 45% of women 75 years and older and 50% of 
women 40-49 reported having a mammogram in the prior year.  Among women 
between 50 and 74 years of age, approximately two-thirds had been screened.  This 
pattern (low use among women in the youngest and oldest age categories) was also 
observed for Pennsylvania women, however use was lower in Luzerne County at both 
extremes of age.  Among residents of Wilkes-Barre, mammography use was materially 
reduced only among women 75 and older.  When the data were examined by level of 
education, mammography use was lowest among those with less than a high school 
education and increased with increasing education.  Similar patterns were observed in 
Luzerne County, Wilkes-Barre and Pennsylvania.  Mammography use was also 
examined by year among women 40 and older.  In 2001, 64% of all women in 
Pennsylvania reported having a mammogram in the prior year.  This figure fell to 55% 
by 2004.  In Luzerne County, mammography use appeared to increase between 2001 
and 2003 and then decrease.  The proportions of women who reported having a 
mammogram in the prior year in 2001, 2002, 2003, 2004, 2005, 2006 were 56%, 54%, 
64%, 59%, 56%, and 50%, respectively.    
 
When all women 40 and older are considered, the proportions of women living in 
Luzerne County who have had either a screening mammogram or clinical exam in the 
previous year are significantly lower than state averages.  Mammography use appears 
to be decreasing over time and is lowest among women younger than 50, older than 74, 
and those with less than a high school education. These data suggest there is 
substantial room for improvement in breast cancer screening rates in this community. 
 
Cancer risk factor analysis:  Population-based data on cancer risk factors among 
adults residing in the six NEPA counties have been examined.  Among 5,154 subjects 
interviewed, 23.4% reported a family history of cancer, 26.7% were current cigarette 
smokers, 24.5% had a body mass index > 30 (obese), and 32.5% reported not 
participating in regular exercise.  The prevalence of cigarette smoking in this population 
is significantly higher than in the general U.S. population, and the prevalence of regular 
exercise is lower.  The proportion of residents of northeast Pennsylvania who reported 
not participating in regular exercise (32.5%) was substantially higher than the 
corresponding figure for the US (22.5%).17  However, the proportions of adults in this 
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population who were overweight (61.1%) or obese (24.5%) were similar to the 
corresponding figures for Pennsylvania in (62% and 25%, respectively) and the US in 
2005 (61% and 24%, respectively).16,17  The mean intake of dietary fiber in this 
population (14.2 grams per day) was below current recommendations (20 grams per 
day or more), and only 12.5% of the population met or exceeded the recommendations.  
The mean percent of calories from fat in this population’s diet was 33%, and 33.5% of 
the population had diets providing more than 35% of calories from fat.  While the mean 
percent of calories from fat is similar to recent estimates for the general US population, 
these data indicate that a third of adults in northeast Pennsylvania consume a diet that 
excessively high in fat and relatively few meet the recommendations for fiber intake.18,19  
 
Of the cancer risk factors examined here, cigarette smoking was the most noteworthy.  
In this population in 2005, 26.7% of adults were current cigarette smokers, a figure that 
was significantly higher than the corresponding figures for Pennsylvania (24%) and the 
US (20%).16,17   While cigarette smoking has been associated with an increased risk of 
colorectal cancer, the increase in risk due to smoking is small.  Among residents of 
northeast Pennsylvania, other risk factors such as sedentary lifestyles and diets rich in 
red meat low in fiber content may contribute more to the high incidence of colorectal 
cancer in this population. 
 
 
PRODUCTS DEVELOPED 
 
During this period of support, cancer institute staff completed a manuscript describing 
the incidence of and mortality from colorectal cancer in Lackawanna County, 
Pennsylvania.  This manuscript, entitled “Colorectal Cancer Incidence and Mortality in 
Northeastern Pennsylvania” has been accepted for publication in the Journal of Registry 
Management.  A pre-print copy of this manuscript has been forwarded to the 
department as a separate submission.  In addition, Cancer Institute investigators have 
presented the results of research conducted under this support at a number of regional 
scientific conferences.  Copies of abstracts presented at these meetings are included in 
the appendix to this report. 
 
Maps showing cancer incidence (SIRs) and mortality (SMRs) by cancer site, sex and 
county for the six-county area in northeast Pennsylvania covered by this project have 
been produced and posted to the World Wide Web.  These maps may be viewed at 
http://www.cancernepa.org/web/professionals/search/home.asp. 
 
No inventions were created nor patents applied for or received during the term of this 
support. 
 
 
ACTUAL ACCOMPLISHMENTS  COMPARED TO ORIGINAL GOALS AND 
OBJECTIVES 
 
In our application, we planned to examine incidence and mortality data for the 10 most 
common cancers occurring in northeast Pennsylvania.  During the course of this project, 
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we obtained and analyzed data for the 23 most common cancer sites.  The desire to not 
overlook less common cancers, which may contribute substantially to the overall cancer 
mortality in this population, and the ready availability of the necessary data allowed us 
to expand the surveillance activity. 
 
Our analysis of cancer risk factors was more limited than anticipated.  The dietary data 
collected in the population-based study was not sufficient to permit more detailed 
examination of dietary factors that may be related to the risk of colorectal cancer.  As 
one consequence, investigators at the Cancer Institute have determined that further 
examination of dietary risk factors for colorectal cancer is warranted.  Further, we have 
agreed to collaborate with investigators at the Pennsylvania State University College of 
Medicine in Hershey, Pennsylvania to conduct further studies of these relationships.  At 
this time, funding has been obtained to conduct a detailed study of diet, smoking, and 
their interactions with genetic factors in the etiology of colorectal cancer in northeast 
Pennsylvania. 
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Table 1.  Standardized incidence ratios† by primary cancer site and sex, northeast 
Pennsylvania, 1998-2002. 
 
Primary site 
  
Total Cases 
  
Both sexes 
  
Men 
  
Women 
 
          
  All sites  22,301  103*  103*  104*  
  Brain  270  102  104  98  
  Breast, female  3,076  -  -  94*  
  Bronchus & lung  3,016  101  115*  85*  
  Colon & rectum  3,247  126*  132*  122*  
  Esophagus  253  117*  131*  80  
  Hodgkin’s disease  133  136*  137*  135*  
  Kidney  560  108  108  107  
  Larynx  221  133*  133*  134  
  Leukemia  566  103  101  104  
  Liver/intra-hepatic bile duct  174  70*  75*  62*  
  Malignant melanoma  536  71*  73*  69*  
  Multiple myeloma  233  89*  84*  94  
  Non-hodgkin’s lymphoma  864  100  99  100  
  Oral cavity  474  102  110  86  
  Ovary  421  -  -  122*  
  Pancreas  512  95  91  99  
  Prostate  2,782  -  80*  -  
  Stomach  394  103  101  105  
  Testis  113  -  127*  -  
  Thyroid  451  158*  128*  165*  
  Urinary bladder  1,255  126*  126*  124*  
  Uterine cervix  210  -  -  140*  
  Uterine corpus  810  -  -  131*  
 
† Standardized incidence ratio = (observed cases/ expected cases) X 100.  SEER 
published rates were used to compute expected numbers. 
* Significantly different from 100, p < 0.05.   
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Table 2.  Standardized incidence ratios† by primary cancer site and sex, northeast 
Pennsylvania, 1999-2003. 
 
Primary site 
  
Total Cases 
  
Both sexes 
  
Men 
  
Women 
 
          
  All sites  22,169  103*  102*  103*  
  Brain  289  109  106  112  
  Breast, female  2,974  -  -  92*  
  Bronchus & lung  3,017  101  117*  82*  
  Colon & rectum  3,169  126*  131*  122*  
  Esophagus  269  123*  137*  86  
  Hodgkin’s disease  133  136*  140*  131  
  Kidney / renal pelvis  574  105  108  100  
  Larynx  208  128*  122*  147*  
  Leukemia  573  103  99  106  
  Liver/intra-hepatic bile duct  170  66*  72*  56*  
  Malignant melanoma  539  70*  72*  67*  
  Multiple myeloma  216  82*  77*  88  
  Non-hodgkin’s lymphoma  836  95  93  97  
  Oral cavity  473  102  112  85*  
  Ovary  406  -  -  118*  
  Pancreas  534  99  98  100  
  Prostate  2,738  -  78*  -  
  Stomach  384  102  102  102  
  Testis  109  -  124*  -  
  Thyroid  477  155*  132*  163*  
  Urinary bladder  1,252  125*  125*  127*  
  Uterine cervix  186  -  -  122*  
  Uterine corpus  825  -  -  135*  
 
† Standardized incidence ratio = (observed cases/ expected cases) X 100.  SEER 
published rates were used to compute expected numbers. 
* Significantly different from 100, p < 0.05.   
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Table 3.  Standardized mortality ratios† by primary cancer site and sex, northeast 
Pennsylvania, 1998-2002. 
 
Primary site 
  
Total Deaths 
  
Both sexes 
  
Men 
  
Women 
         
  All sites  9,766  103*  105*  101 
  Brain  185  93  96  89 
  Breast, female  739  -  -  104 
  Bronchus & lung  2,381  90*  98  79* 
  Colon & rectum  1,237  123*  123*  122* 
  Esophagus  237  115*  117  111 
  Hodgkin’s disease  29  126  100  155 
  Kidney / renal pelvis  195  98  102  94 
  Larynx  73  114  118  100 
  Leukemia  393  109  109  109 
  Liver/intra-hepatic bile duct  192  88  89  87 
  Malignant melanoma  128  108  107  109 
  Multiple myeloma  165  88  88  88 
  Non-hodgkin’s lymphoma  421  107  109  106 
  Oral cavity  112  91  100  77 
  Ovary  280  -  -  114* 
  Pancreas  491  95  93  97 
  Prostate  544  -  100  - 
  Stomach  242  110  104  110 
  Testis  5  -  -¶    - 
  Thyroid  19  86  -  107 
  Urinary bladder  240  111  119*  96 
  Uterine cervix  62  -  -  97 
  Uterine corpus  144  -  -  118 
 
† Standardized mortality ratio = (observed deaths/ expected deaths) X 100.  Published 
US rates were used to compute expected numbers. 
* Significantly different from 100, p < 0.05.   
¶  Sample includes five or fewer deaths. 
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Table 4.  Standardized mortality ratios† by primary cancer site and sex, northeast 
Pennsylvania, 1999-2003. 
 
Primary site 
  
Total Deaths 
  
Both sexes 
  
Men 
  
Women 
         
  All sites  9,807  105*  108*  103 
  Brain  188  95  97  93 
  Breast, female  725  -  -  105 
  Bronchus & lung  2,385  91*  100  79* 
  Colon & rectum  1,220  125*  126*  124* 
  Esophagus  250  121*  126*  107 
  Hodgkin’s disease  31  129  117  142 
  Kidney / renal pelvis  201  100  103  94 
  Larynx  82  128*  142*  88 
  Leukemia  393  109  105  113 
  Liver/intra-hepatic bile duct  191  84*  84*  85 
  Malignant melanoma  118  96  95  98 
  Multiple myeloma  153  81*  75*  86 
  Non-hodgkin’s lymphoma  435  115*  115  116* 
  Oral cavity  116  91  106  65* 
  Ovary  264  -  -  105 
  Pancreas  502  97  95  99 
  Prostate  522  -  102  - 
  Stomach  230  110  101  120 
  Testis  5  -  -¶  - 
  Thyroid  23  85  55*  106 
  Urinary bladder  254  118*  120*  114 
  Uterine cervix  61  -  -  98 
  Uterine corpus  145  -  -  119 
 
† Standardized mortality ratio = (observed deaths/ expected deaths) X 100.  Published 
US rates were used to compute expected numbers. 
* Significantly different from 100, p < 0.05.   
¶  Sample includes five or fewer deaths. 
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Table 5. Breast cancer screening practices among women 40 years and older in 
Pennsylvania, Luzerne County and Wilkes-Barre, 2001-2006. 
 
Screening Exam 
Pennsylvania* 
(n=11,031) 
Luzerne County 
(n=942) 
Wilkes-Barre 
(n=149) 
Clinical Breast Exam in Prior Year 65% 60%† 58% 
    
Mammogram in Prior Year 62% 58%† 61% 
    
Clinical Breast Exam + 
Mammogram in Prior 2 Years. 
(Age 50+) 
 
 
70% 
 
 
70% 
 
 
66% 
* Pennsylvania figures are for 2001-2004 only. 
† Statistically different from the figure for Pennsylvania. 
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Table 6. Mammography use* among women 40 and older in Pennsylvania, Luzerne 
County and Wilkes-Barre by age and education, 2001-2006. 
 Pennsylvania† 
% 
Luzerne County 
% 
Wilkes-Barre 
% 
Age, 40-49 
50-64 
65-74 
75+ 
56 
67 
68 
54 
50 
65 
68 
45 
64 
67 
72 
44 
    
Education, 
Less than High School 
High School 
Some College 
College Graduate 
 
50 
59 
62 
66 
 
46 
57 
58 
65 
 
36 
62 
65 
69 
* Percent of women in each category who reported having a mammogram in the past 
year. 
† Pennsylvania figures are for 2001-2004 only. 
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APPENDIX 
 
 
Presentations at scientific meetings 
During this period of funding, Cancer Institute investigators have made a number of 
presentations at regional and international scientific meetings.  Abstracts for these 
presentations are included in this appendix. 
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Do spiritual practices influence colorectal cancer screening?  I. Prokup and S. 
Lesko (Northeast Regional Cancer Institute, Scranton, Pennsylvania, 18510) 
 
Colorectal cancer (CRC) is the second leading cause of cancer death in the US.  
Despite evidence that CRC screening reduces mortality, US screening rates remain 
low.  The prevalence of CRC screening in northeast Pennsylvania is lower than in 
Pennsylvania as a whole or the US.  It is not clear why screening rates are low in this 
region.  One hypothesis that has not been extensively studied is whether CRC 
screening is associated with religion or spiritual practices.  We conducted a cross-
sectional analysis of CRC screening in a population-based study of 782 adults 50+ 
years of age with no personal history of CRC.  Self-reported history of CRC screening 
was obtained by telephone interview using random digit dialing.   Subjects who reported 
having had screening sigmoidoscopy or colonoscopy (endoscopy) within 5 years (n = 
256) were compared to subjects who reported having never been screened or only 
more than 5 years previously.  Subjects were classified by religion (Catholic, Protestant, 
Jewish, or other/none), and The Duke University Religion Index was used to measure 
spiritual beliefs and practices.  Logistic regression analysis was used to study the 
relationship between endoscopy screening and religion and spirituality, while controlling 
for age.  Intrinsic spirituality was not associated with having been screened in the 
previous five years.  Compared to Catholics, Jews were more likely to have been 
screened (adjusted odds ratio [OR] 4.7, 95% Confidence Interval [CI]1.5,14.7); men and 
women who engaged in private spiritual activities (prayer/meditation/bible study) at least 
once a day (compared to those who rarely did so), and men who participated in 
organized worship at least once a week (compared to those who worshiped once a year 
or less) were less likely to have been screened (OR 0.59, 95%CI 0.38,0.91) and (OR 
0.51, 95%CI 0.25,1.0), respectively.  These data suggest that spiritual practices may 
help identify subjects who could benefit from efforts designed to increase colorectal 
cancer screening. 
Presented at the annual meeting of the Society for Epidemiologic Research, 
Toronto, Canada, June 2005. 
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Factors associated with cigarette smoking in Northeast Pennsylvania 
T. Coleman and S.M. Lesko (Northeast Regional Cancer Institute, Scranton, PA 18510) 
Tobacco use, particularly cigarette smoking, remains the number one cause of 
preventable disease and death in the U.S.  In the six-county area of Northeast 
Pennsylvania, the prevalence of current cigarette smoking in 2003 (28.7%) was 
significantly higher than in Pennsylvania as a whole and the U.S.  We sought to identify 
factors associated with current smoking in this high-risk population.  We conducted a 
cross-sectional analysis of current cigarette smoking in a population-based study of 
adults aged 18 and older.  Self-reported history of tobacco use was obtained by 
telephone interview using random digit dialing.  Current smokers (defined as those who 
had smoked at least 100 cigarettes in their lifetime and continue to smoke, n=337) were 
compared to subjects who smoked fewer than 100 cigarettes in their lifetimes (n=670).  
We used logistic regression to study the relationship between smoking status and the 
following variables:  age, sex, race, educational attainment, marital and employment 
status, place of residence (urban v. rural), and usual source of health care.  The odds of 
smoking decreased with increasing age (adjusted odds ratio [OR] for one-year 
increment of age = 0.96, 95% Confidence Interval [CI] 0.95-0.97).  The following were 
also associated with current smoking: male sex (OR 1.5, 95% CI 1.1-2.0), non-white 
race (OR 0.3, 95%CI 0.15-0.76), college education (OR 0.37, 95%CI 0.25-0.54), not 
having a private physician as usual source of healthcare (OR 1.9, 95%CI 1.2-3.1), and 
being divorced/separated (OR 3.2, 95%CI 2.1-5.0).  Employment status and place of 
residence were not associated with current smoking.  The data suggest that not having 
a private physician and being divorced/separated, male, and less-well educated 
increase one’s risk for cigarette smoking in this community, while non-whites are at a 
significantly lower risk than the majority white population.  These characteristics may 
assist tobacco control specialists deliver more targeted interventions. 
Presented at the annual meeting of the Society for Epidemiologic Research, 
Toronto, Canada, June 2005. 
Presented at the Pennsylvania Cancer Control Consortium Research Summit, 
Harrisburg, PA, November 2005. 
Presented at Health Sciences Research 2006, Scranton, PA, April 2006. 
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Barriers to the use of adjuvant chemotherapy in stage III colorectal cancer 
Samuel M Lesko, MD, MPH and Trudy Coleman, PhD, Northeast Regional Cancer 
Institute, Scranton, PA, USA 
 
Background: Colorectal cancer is the second leading cause of cancer death in the US. 
Despite clinical guidelines recommending adjuvant chemotherapy for all patients with 
stage III colorectal cancer, many patients do not receive this treatment. 
 
Objectives: The authors sought to identify barriers to the use of adjuvant chemotherapy 
in patients with this common stage of colorectal cancer. 
 
Methods: Cross-sectional analysis of colorectal cancer case data from a population-
based cancer registry in Northeast Pennsylvania. All cases with stage III 
adenocarcinoma of the colon or rectum diagnosed in 1998 through 2002 were included. 
The chi-squared test was used to evaluate relationships between age, sex, health 
insurance coverage, place of residence (urban v. rural), year of diagnosis, and anatomic 
site within the bowel and adjuvant chemotherapy use. Multiple logistic regression was 
used to control for confounding in multivariable models. 
 
Results: A total of 512 patients with stage III colorectal cancer (mean age 70.2 yrs) 
were studied. Of these, 302 (59%) received chemotherapy in addition to surgery as first-
course therapy. In bivariate analyses, patient age, year of diagnosis, and anatomic site 
within the colon were associated with the use of adjuvant therapy. Compared to patients 
younger than 70 years of age, the odds ratio (OR) for those 70+ was 0.2 (95% 
Confidence Interval [CI], 0.13 - 0.29); compared to patients diagnosed in 1998, the OR 
for the use of adjuvant therapy in 2002 was 0.54 (95% CI, 0.32 - 0.93); and compared to 
patients with cancer of the rectum/rectosigmoid, the OR for cancers of the colon was 
0.6 (95% CI, 0.39 - 0.91). Patient sex, insurance coverage, and place of residence were 
not associated with the use of this treatment. In a multivariable model including all of 
these factors, only patient age was associated with the use of adjuvant chemotherapy; 
compared to patients less than 70 years of age, the OR for the use of adjuvant therapy 
among those 70+ was 0.2 (95 % confidence interval, 0.13 - 0.30). 
 
Conclusions: Despite clinical guidelines supporting the routine use of adjuvant 
chemotherapy for all patients with stage III colorectal cancer, only about 60% receive this 
treatment. Advancing age is the only significant barrier to the use of adjuvant 
chemotherapy in these data. Further research is needed to determine the extent to which 
other factors (patient preference, co-morbidity, and physician recommendation) influence 
the use of adjuvant chemotherapy in stage III colorectal cancer. 
Presented at the International Conference in Pharmacoepidemiology, Nashville, 
TN, August 2005. 
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Use of adjuvant chemotherapy in stage III colorectal cancer in Northeast 
Pennsylvania 
Samuel M Lesko, MD, MPH and Trudy Coleman, PhD, Northeast Regional Cancer 
Institute, Scranton, PA, USA 
 
Program purpose and need: Colorectal cancer is the second leading cause of cancer 
death in the US.  According to clinical guidelines, all patients with stage III colorectal 
cancer should receive adjuvant chemotherapy (ACT).  However, many do not. 
 
Objectives: The authors sought to identify factors associated with the use of ACT in 
patients with stage III colorectal cancer. 
 
Methods: Cross-sectional analysis of data from a population-based cancer registry in 
Northeast Pennsylvania. All cases with stage III adenocarcinoma of the colon or rectum 
diagnosed in 1998 through 2002 were included.  Multiple logistic regression was used to 
control for confounding and to evaluate relationships between age, sex, health 
insurance coverage, place of residence (urban v. rural), year of diagnosis, and anatomic 
site within the bowel and ACT use.  
 
Results: Of 512 patients with stage III colorectal cancer, 302 (59%) received 
chemotherapy in addition to surgery as first-course therapy.  Patient age and year of 
diagnosis were associated with the use of ACT.  Compared to patients younger than 70 
years of age, the odds ratio (OR) for those 70+ was 0.2 (95% Confidence Interval [CI], 
0.13 - 0.30); compared to patients diagnosed in 1998, the OR for those diagnosed in 
2002 was 0.50 (95% CI, 0.27 - 0.94); and compared to patients with insurance, the OR 
for those with none was 0.61 (95% CI, 0.34 – 1.1).  Sex, anatomic site, and place of 
residence were not associated with ACT use.   
 
Conclusions: Despite clinical guidelines supporting the routine use of ACT for all 
patients with stage III colorectal cancer, only about 60% receive this treatment. 
Advancing age is the most important barrier to the use of ACT in these data. Further 
research is needed to determine the extent to which other factors (patient preference, 
co-morbidity, and physician recommendation) influence the use of ACT in stage III 
colorectal cancer. 
Presented at the Pennsylvania Cancer Control Consortium Research Summit, 
Harrisburg, PA, November 2005. 
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A population-based study of predictors of colorectal cancer screening in a  
high-risk population. 
Ilene Prokup, MS, APRN,BC, Samuel Lesko, MD, MPH.  Northeast Regional Cancer 
Institute, University of Scranton Campus, Scranton PA 18510, 570-941-7984, 
prokupi2@uofs.edu 
 
Colorectal cancer (CRC) is the second leading cause of cancer death in the U.S.  
Despite evidence that CRC screening can reduce mortality, screening rates remain low. 
In the 6-county area of Northeast Pennsylvania, incidence and mortality are significantly 
higher than state and national rates.  We sought to identify factors associated with 
screening in this high-risk population.  We conducted a case-control analysis of CRC 
screening in a population-based study of 819 adults 50+ years of age with no personal 
history of CRC.  Self-reported history of CRC screening was obtained by telephone 
interview using random digit dialing. Cases were defined as those having had an 
endoscopy (sigmoidoscopy or colonoscopy) within 5 years (N=261).  Controls were 
subjects who reported endoscopy more than 5 years previously or never.  We used 
logistic regression to study the relationship between endoscopy and the following 
variables:  age, sex, marital status, education, place of residence, occupation, body 
mass index, exercise, smoking, alcohol use, personal history of cancer, family history of 
cancer, other cancer screenings, and other health screenings.  The following were 
associated with recent endoscopy screening:  male sex (adjusted Odds Ratio 1.7, 95% 
Confidence Interval 1.2-2.4), personal history of cancer (OR 1.8, 95%CI 1.2-2.7), family 
history of cancer (OR1.7, 95%CI 1.2-2.4), other cancer screenings (OR 2.2, 95%CI 1.4-
3.3), and other screenings (OR 2.5, 95%CI 1.2-5.3).  The data suggest that being male, 
having a personal and family history of cancer, and being current with cancer and other 
health screenings  predict screening for colorectal cancer with endoscopy in a 
population-based study. 
Presented at the Pennsylvania Cancer Control Consortium Research Summit, 
Harrisburg, PA, November 2005. 
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Adjuvant chemotherapy in stage III colorectal cancer: barriers and predictors  
of use  
Samuel M Lesko and Trudy Coleman (Northeast Regional Cancer Institute) 
 
Colorectal cancer is the second leading cause of cancer death in the US. Despite 
guidelines recommending the use of adjuvant chemotherapy for patients with stage III 
colorectal cancer, many patients do not receive this treatment. The authors sought to 
identify barriers to the use of adjuvant chemotherapy in patients with stage III colorectal 
cancer. A cross-sectional analysis of data from a population-based cancer registry in 
Northeast Pennsylvania was conducted. Cases with stage III adenocarcinoma of the 
colon or rectum diagnosed in 1998 - 2002 were studied. Multiple logistic regression was 
used to evaluate relationships between age, sex, health insurance coverage, place of 
residence (urban v. rural), year of diagnosis, and anatomic site within the bowel and 
adjuvant chemotherapy use. Of 512 patients with stage III colorectal cancer (mean age 
70.2 yrs), 302 (59%) received adjuvant chemotherapy. In the multivariable model, 
patient age was associated with the use of adjuvant chemotherapy; compared to 
patients less than 70 years of age, the odds ratio (OR) for the use of adjuvant therapy 
among those 70+ was 0.2 (95 % confidence interval [CI], 0.13 - 0.30). Adjuvant 
chemotherapy use was marginally lower among those with no health insurance (OR = 
0.61; 95% CI, 0.43 – 1.1). Despite clinical guidelines supporting the routine use of 
adjuvant chemotherapy for all patients with stage III colorectal cancer, only about 60% 
receive this treatment. Advancing age was the greatest barrier to the use of adjuvant 
chemotherapy in these data. Further research is needed to determine the extent to 
which other factors (patient preference, co-morbidity, and physician recommendation) 
influence the use of adjuvant chemotherapy in stage III colorectal cancer. 
Health Sciences Research 2006, Scranton, PA, April 2006. 
Presented at Health Sciences Research 2006, Scranton, PA, April 2006. 
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Religion, spiritual practices and colorectal cancer screening 
I. Prokup and S. Lesko (Northeast Regional Cancer Institute) 
 
Colorectal cancer (CRC) is the second leading cause of cancer death in the US.  
Despite evidence that CRC screening reduces mortality, US screening rates remain 
low.  The prevalence of CRC screening in Northeast Pennsylvania is lower than in 
Pennsylvania as a whole or the US.  It is not clear why screening rates are low in this 
region.  One hypothesis that has not been extensively studied is whether CRC 
screening is associated with religion or spiritual practices.  We conducted a cross-
sectional analysis of CRC screening in a population-based study of 782 adults 50+ 
years of age with no personal history of CRC.  Self-reported history of CRC screening 
was obtained by telephone interview using random digit dialing.   Subjects who reported 
having had screening sigmoidoscopy or colonoscopy (endoscopy) within 5 years (n = 
256) were compared to subjects who reported having never been screened or only 
more than 5 years previously.  Subjects were classified by religion (Catholic, Protestant, 
Jewish, or other/none), and The Duke University Religion Index was used to measure 
spiritual beliefs and practices.  Logistic regression analysis was used to study the 
relationship between endoscopy screening and religion and spirituality, while controlling 
for age.  Intrinsic spirituality was not associated with having been screened in the 
previous five years.  Compared to Catholics, Jews were more likely to have been 
screened (adjusted odds ratio [OR] 4.7, 95% Confidence Interval [CI]1.5,14.7); men and 
women who engaged in private spiritual activities (prayer/meditation/bible study) at least 
once a day (compared to those who rarely did so), and men who participated in 
organized worship at least once a week (compared to those who worshiped once a year 
or less) were less likely to have been screened (OR 0.59, 95%CI 0.38,0.91) and (OR 
0.51, 95%CI 0.25,1.0), respectively.  These data suggest that spiritual practices may 
help identify subjects who could benefit from efforts designed to increase colorectal 
cancer screening. 
Presented at Health Sciences Research 2006, Scranton, PA, April 2006. 
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The effect of age on the treatment of stage III colorectal cancer 
Samuel M Lesko and Trudy Coleman (Northeast Regional Cancer Institute, 
Scranton, PA, 18510) leskos2@scranton.edu  
 
Colorectal cancer is the second leading cause of cancer death in the US. Despite 
guidelines recommending the use of adjuvant chemotherapy for patients with stage III 
colorectal cancer, many patients do not receive this treatment. The authors sought to 
identify barriers to the use of adjuvant chemotherapy in patients with stage III colorectal 
cancer. A cross-sectional analysis of data from a population-based cancer registry in 
Northeast Pennsylvania was conducted. Cases with stage III adenocarcinoma of the 
colon or rectum diagnosed in 1998 - 2002 were studied. Multiple logistic regression was 
used to evaluate relationships between age, sex, health insurance coverage, place of 
residence (urban v. rural), year of diagnosis, and anatomic site within the bowel and 
adjuvant chemotherapy use. Of 512 patients with stage III colorectal cancer (mean age 
70.2 yrs), 302 (59%) received adjuvant chemotherapy. In the multivariable model, 
patient age was associated with the use of adjuvant chemotherapy; compared to 
patients less than 70 years of age, the odds ratio (OR) for the use of adjuvant therapy 
among those 70+ was 0.2 (95 % confidence interval [CI], 0.13 - 0.30). Adjuvant 
chemotherapy use was marginally lower among those with no health insurance (OR = 
0.61; 95% CI, 0.43 – 1.1). Despite clinical guidelines supporting the routine use of 
adjuvant chemotherapy for all patients with stage III colorectal cancer, only about 60% 
receive this treatment. Advancing age was the greatest barrier to the use of adjuvant 
chemotherapy in these data. Further research is needed to determine the extent to 
which other factors (patient preference, co-morbidity, and physician recommendation) 
influence the use of adjuvant chemotherapy in stage III colorectal cancer. 
Presented at the 2006 Congress of Epidemiology, Seattle, WA, June 2006. 
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Screening among advanced stage cervical cancer cases in Pennsylvania, 2000-
2001: screening failure or failure to screen. 
Samuel M. Lesko, MD, MPH and Trudy Coleman, PhD.  Northeast Regional Cancer 
Institute, Scranton/Wilkes-Barre, PA. 
Background: Screening for cervical cancer saves lives by causing the diagnosis of 
early stage lesions (pre-invasive lesions and early invasive cancers) in asymptomatic 
women.  Despite the wide availability of the PAP test with proven effectiveness, women 
are diagnosed with advanced stage cervical cancer in Pennsylvania each year.  The 
extent to which these diagnoses represent failures of the screening test is unknown. 
Objectives:  The investigators sought to determine the number of women diagnosed 
with advanced stage cervical cancer in Pennsylvania each year, despite having been 
previously screened and to identify the reason(s) their cancers were not diagnosed 
earlier. 
Methods:  Follow-back study of invasive cervical cancer cases reported to the 
Pennsylvania cancer registry in 2000 and 2001.  Data were obtained from the cancer 
registry, by personal interview, and medical record review.  Multiple logistic regression 
was used to examine the relationship between the risk of advanced (regional and 
distant) stage cancer and screening history while controlling for potential confounders. 
Results:  Of 116 cases of cervical cancer diagnosed in 2000-2001 (mean age 50.2 
years, 49.1% advanced stage), 75.9% reported having a prior PAP test.  Among 
advanced stage cases, 66.7% reported a prior PAP.  This is the equivalent of 163 (95% 
CI 129-192) cases of advanced stage cervical cancer diagnosed each year in 
Pennsylvania, despite prior screening.  Compared to patients never screened, the odds 
ratios for early stage cancer were 2.3 (95% CI 0.88-6.1), 3.5 (95% CI 1.2-10), and 2.9 
(95% CI 0.88-9.5) among women who had been screened ever, screened regularly, and 
screened within the prior year, respectively.  Among all cases with advanced stage 
disease, 33.3% reported never having been screened, 40.4% reported only episodic 
screening or screening in the distant past, and 26.3% reported having annual PAP 
tests.  Of this latter group, 2/3 (17.5% of all advanced stage cases) reported having a 
prior abnormal PAP, and 1/3 (8.8% of all advanced stage cases) reported all prior tests 
were normal. 
Conclusions: These data confirm that, as currently practiced in Pennsylvania, regular 
PAP testing increases the odds of detecting cervical cancer at an early, treatable stage 
by more than three-fold.  Failure to screen regularly, or at all, was the greatest 
contributor to the risk of advanced stage cancer, accounting for nearly ¾ of all 
advanced cases.  Fewer than 9% of advanced stage cancers were missed by a prior 
normal test.  These data also suggest that better follow-up of abnormal PAP results 
could reduce the number of advanced stage cases by as much as 17.5%.  The number 
of Pennsylvania women diagnosed each year with advanced stage cervical cancer 
despite prior screening (~160) is not large but could be reduced by more consistent use 
of existing technology. 
Presented at the Penn State Cancer Institute Annual Research Retreat, Hershey, 
PA, September 2006. 
Presented at the Pennsylvania Cancer Control Consortium Research Summit, 
Harrisburg, PA, November 2006. 
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Screening among advanced stage colorectal cancer cases in Pennsylvania, 2000-
2001. 
Samuel M. Lesko, MD, MPH and Trudy Coleman, PhD.  Northeast Regional Cancer 
Institute, Scranton/Wilkes-Barre, PA. 
 
Background: Screening for colorectal cancer saves lives by detecting cancer when the 
disease is highly curable.  Despite the wide availability of effective screening 
procedures, a substantial proportion of incident colorectal cancers are diagnosed at 
advanced stages in Pennsylvania each year.  The extent to which these diagnoses 
represent failures of the screening test is unknown. 
Objectives:  The investigators sought to determine the number of patients diagnosed 
with advanced stage colorectal cancer in Pennsylvania each year despite having been 
previously screened and to identify the reason(s) these cancers were not diagnosed 
earlier. 
Methods:  Follow-back study of colorectal cancer cases reported to the Pennsylvania 
cancer registry in 2000 and 2001.  Data were obtained from the cancer registry, by 
interview, and medical record review.  Logistic regression was used to examine the 
relationship between the risk of advanced (regional and distant) stage cancer and 
screening history while controlling for confounding. 
Results:  Of 795 cases of colorectal cancer (mean age 66.4 years, 55.1% male, 94.1% 
white, 57.7% advanced stage), 54% (95% Confidence Interval [CI] 50.2%-57.9%) 
reported having ever been screened.  Among advanced stage cases, 48.4% (an 
average of 2,416 cases per year in Pennsylvania) reported prior screening.  Compared 
to patients never screened, the odds ratios for early stage cancer were 1.6 (95% CI 1.1-
2.2), 2.3 (95% CI 1.3-4.2), and 1.5 (95% CI 0.67-3.5) among patients who had ever 
been screened, screened first before age 55 and repeated at the correct interval, and 
screened first before age 55 but repeated at incorrect intervals, respectively.  The 
corresponding odds ratios were 2.0 (95% CI 1.2-3.2), 1.8 (95% CI 0.84-3.6), and 1.6 
(95% CI 1.0-2.4) among those screened by colonoscopy, sigmoidoscopy and FOBT, 
respectively.  The majority of advanced stage cases (74.3%) had not been screened 
according to a currently recommended protocol, but 11.8%, 6.8% and 8.0% had been 
previously screened within the recommended interval by colonoscopy, sigmoidoscopy 
or FOBT, respectively.    
Discussion: In Pennsylvania, screening for colorectal cancer according to 
recommended protocols increases the odds of detecting this cancer at an early, 
treatable stage by more than two-fold.  Failure to screen properly accounted for 74% of 
all advanced cases, but 26% of advanced stage cases were missed by one or more 
screening test.  The number of Pennsylvanians diagnosed each year with advanced 
stage colorectal cancer despite prior screening (~2,400) is large but could be reduced 
substantially by increasing compliance with existing screening guidelines. 
Presented at Health Sciences Research 2007, Scranton, PA, February 2007. 
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Predictors of adjuvant chemotherapy in stage III colorectal cancer  
Samuel M Lesko and Trudy Coleman (Northeast Regional Cancer Institute) 
 
Background: Colorectal cancer is the second leading cause of cancer death in the US. 
Despite guidelines recommending the use of adjuvant chemotherapy for patients with 
stage III colorectal cancer, many patients do not receive this treatment.  
Objectives: The authors sought to identify barriers to the use of adjuvant chemotherapy 
in patients with stage III colorectal cancer.  
Methods: A cross-sectional analysis of data from a population-based cancer registry in 
Northeast Pennsylvania was conducted. Cases with stage III adenocarcinoma of the 
colon or rectum diagnosed in 2003-2005 were studied; patients receiving chemotherapy 
were compared to those who did not. The student’s t-test was used to compare 
continuous variables, chi-square test was used to compare categorical variables, and 
multiple logistic regression was used to evaluate relationships between adjuvant 
chemotherapy use and multiple risk factors, while controlling for confounding.  The 
following factors were examined: age, sex, health insurance coverage, county of 
residence (urban v. rural), year of diagnosis, co-morbid conditions, and anatomic site 
within the bowel.  
Results: Of 252 patients with stage III colorectal cancer (mean age 71.6 yrs), 126 
(50%) received adjuvant chemotherapy.  Patients receiving adjuvant chemotherapy 
were younger (mean age 66.3 yrs) than those not treated (mean age 76.9 yrs; p < 
0.001).  In bivariate analyses, adjuvant chemotherapy use was significantly more 
common in men (odds ratio [OR] 1.8; 95% confidence interval [CI] 1.1-3.0) and patients 
with private insurance (OR = 2.6; 95% CI 1.4-4.6) and less common in patients with 
congestive heart failure (OR = 0.38; 95% CI 0.15-0.94) or non-ischemic heart disease 
(OR = 0.4; 95% CI 0.2-0.82).  In a multivariable model controlling for co-morbid 
conditions, patient age remained significantly associated with the use of adjuvant 
chemotherapy; compared to patients less than 75 years of age, the OR for the use of 
adjuvant therapy among those 75+ was 0.28 (95 % CI, 0.14 - 0.54).  In this model, the 
ORs for congestive heart failure and non-ischemic heart disease were 0.49 (95% CI, 
0.18-1.3) and 0.62 (95% CI, 0.28-1.3), respectively.  
Conclusions: Despite clinical guidelines supporting the routine use of adjuvant 
chemotherapy for all patients with stage III colorectal cancer, only about half receive this 
treatment. After controlling for co-morbid conditions, advanced age remained a 
significant barrier to the use of adjuvant chemotherapy in these data. Further research 
is needed to determine whether other factors (patient preference and physician 
recommendation) influence the use of adjuvant chemotherapy in stage III colorectal 
cancer. 
Presented at Health Sciences Research 2007, Scranton, PA, February 2007. 
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Factors associated with the intention to continue cigarette smoking in Northeast 
Pennsylvania 
T. Coleman and S.M. Lesko (Northeast Regional Cancer Institute, Scranton, PA 18510) 
 
Background: Tobacco use, particularly cigarette smoking, remains the number one 
cause of preventable disease and death in the U.S.  The prevalence of cigarette 
smoking in Northeast Pennsylvania (26.7% in 2005) is significantly higher than in PA 
and the U.S. Among current smokers in this region, 23.3% (95% Confidence Interval 
[CI] 17.1%, 29.5%) had no plans to quit.  This proportion did not change significantly 
between 2003 and 2005.  
Objective:  We sought to identify factors associated with the intention to continue 
smoking in this high-risk population.   
Methods:  We conducted a cross-sectional analysis of quitting intentions in a 
population-based study of 714 current smokers.  Between January 2003 and December 
2005, self-reported history of tobacco use and quitting intention was obtained by 
telephone interview using random digit dialing.  Smokers who did not intend to quit 
(n=179) were compared to those who did (n=535).  We used logistic regression to study 
the relationship between intention to quit and the following: age, sex, religion, marital 
and employment status, age started smoking, healthcare professionals’ screening for 
smoking and advice to quit, prior attempts at quitting, alcohol use, use of other tobacco 
products, and change in body mass index (BMI) since age 18.   
Results: The following were associated with the intention to continue smoking: age 
(compared to those younger than 30, the odds ratios (OR) for smokers 45-64 and 65+ 
were 2.3 (95% CI 1.2-4.5) and 3.8 (95% CI, 1.6-8.9), respectively; prior quit attempts 
(compared to those who tried quitting 1-3 times, the OR for those with no prior quit 
attempts was 4.0 (95% CI 2.5-6.3); advice to quit by a health professional (compared to 
those who had been advised to quit, the OR among those not advised to quit was 2.3 
(95% CI 1.5-3,6) and BMI (compared to those with a stable BMI, the ORs for smokers 
whose BMI decreased or increased by 2.5-7.4 units were  3.0 (95% CI 1.5-5.9) and  1.8 
(95% CI 1.1-3.0), respectively).  Results in men and women were similar.   
Conclusions:  These data suggest that age >45, never having tried to quit for at least 
one day, and not having been advised to quit by a healthcare professional increase risk 
of continued smoking.  The relation between BMI and smoking intention is complex and 
non-linear.  These observations may assist health professionals deliver more targeted 
interventions to help current smokers quit. 
Presented at Health Sciences Research 2007, Scranton, PA, February 2007. 
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TCCAP: a Targeted Awareness Program to Address Colorectal Cancer Disparities 
in Northeast Pennsylvania 
Samuel M. Lesko, MD, MPH, Regina Schmid-Allen, MHA, and Laura Toole, LCSW, 
Northeast Regional Cancer Institute, 334 Jefferson Avenue, Scranton, PA 18510 
 
Purpose: Because of high colorectal cancer (CRC) incidence and mortality in their 
northern Appalachian community, the authors developed a Targeted Colorectal Cancer 
Awareness Program (TCCAP), a multi-faceted education program designed to improve 
detection of and reduce mortality from CRC by increasing awareness and screening.   
Methods: TCCAP is a three-year program delivering information on CRC (risk and 
screening strategies) to community residents and primary healthcare providers.  It uses 
the media, written materials and educational programs for the public, and academic 
detailing and didactic presentations for healthcare providers. Post-intervention 
questionnaires were used to assess community members’ screening intentions and 
healthcare professionals’ screening plans/practices.  Population surveys and cancer 
registry data were used to document screening prevalence and stage at diagnosis. 
Results: Following an education program, 63% of community residents reported an 
intention to be screened.  Among healthcare professionals, 93% planned to modify 
professional behavior after attending a lecture, and 69% reported increased screening 
following a detailing session. Since the start of the program, the prevalence of screening 
colonoscopy increased from 33% to 41% (p < .001), and the proportion of patients 
diagnosed with local stage CRC increased from 31% to 38% (p < 0.0001).  
Implications: The change in stage at diagnosis suggests that the disparity in CRC 
mortality is decreasing; this change means that each year, 13 fewer incident CRC cases 
can expect to die of their disease. 
Sustainability: How long benefits will persist after the program ends is unknown, 
however, its modest cost ($4,102/year of life saved) suggests the program is 
sustainable. 
Presented at Bridging the Health Care Divide: Research and Programs to 
Eliminate Cancer Disparities, New Orleans, LA, April 2007. 
 
 
 
